Bevatas 300mg Injection

• Cancer of colon and rectum
• Ovarian cancer
• Cervical cancer
• Kidney cancer
• Brain tumor
• Non-small cell lung cancer

Most side effects of Bevatas 300mg Injection don't require medical attention as they may disappear as your body adjusts to the medicine.
Some common side effects include:

• Nosebleeds
• Headache
• High blood pressure
• Inflammation of the nose
• Protein in urine
• Taste change
• Dry skin
• Hemorrhage
• Increased lacrimation
• Back pain
• Exfoliative dermatitis

In case of any serious or persistent effect, seek medical attention immediately.

• Bevatas 300mg is available in injection form and is advised to be taken as per the doctor's prescription. It can only be given intravenously by a doctor or nurse under strict medical supervision.Taking this injection in the wrong way may give you severe side effects.
• In case of overdose, contact your healthcare provider or doctor and they will provide you with medical attention. Missing or overdosing will impact the overall health of the patients and may also have side effects. So, it is always advisable to follow the prescription of the doctor strictly.
  

Bevatas 300mg injection is an anti-angiogenic medication with Bevacizumab (300mg) as an active ingredient. It works by blocking a specific protein known as vascular endothelial growth factor (VEGF). By blocking the action of specific protein it stops the formation of blood vessels that bring oxygen and nutrients to cancerous cells. Thereby, stop the growth & multiplication of cancer cells & slow down the progression of disease.

• Lee, S. P., Hsu, H. C., Tai, Y. J., Chen, Y. L., Chiang, Y. C., Chen, C. A., & Cheng, W. F. (2019). Bevacizumab dose affects the severity of adverse events in gynecologic malignancies. Frontiers in Pharmacology, 10, 426. https://pubmed.ncbi.nlm.nih.gov/31105567/
• Cobleigh, M. A., Langmuir, V. K., Sledge, G. W., Miller, K. D., Haney, L., Novotny, W. F., ... & Vassel, A. (2003, October). A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. In Seminars in oncology (Vol. 30, pp. 117-124). WB Saunders. https://pubmed.ncbi.nlm.nih.gov/14613032/
• Gordon, M. S., & Cunningham, D. (2005). Managing patients treated with bevacizumab combination therapy. Oncology, 69(Suppl. 3), 25-33. https://pubmed.ncbi.nlm.nih.gov/16301833/
• Bergsland, E., & Dickler, M. N. (2004). Maximizing the potential of bevacizumab in cancer treatment. The Oncologist, 9(S1), 36-42. https://pubmed.ncbi.nlm.nih.gov/15178814/
• Falk, A. T., Barrière, J., François, E., & Follana, P. (2015). Bevacizumab: a dose review. Critical reviews in oncology/hematology, 94(3), 311-322. https://pubmed.ncbi.nlm.nih.gov/25703583/